Loading data for ALVOW — first visit, this takes a few seconds.
Alvotech (ALVOW)
NasdaqGM: ALVOW
· Real-Time Price · USD
0.49
+0.00 (0.00%)
At close: Aug 25, 2026, 4:06 PM
The price, the headline numbers and the latest news, in one place.
Alvotech (ALVOW) Stock Price, Analysis & Data
0.00% (1D)
No data available
| Bid | 1.24 |
| Market Cap | n/a |
| Revenue (ttm) | 494.61M |
| Net Income (ttm) | -179.59M |
| 0.18 | |
| n/a | |
| n/a | |
| n/a | |
| P/B (ttm) | -0.91 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 1.3 |
| Volume | 101 |
| Avg. Volume (20D) | |
| Open | 1.52 |
| Previous Close | 0.49 |
| Day's Range | 0.38 - 0.49 |
| 52-Week Range | 0.38 - 0.49 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ALVOW
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing s...
IPO Date Jul 17, 2026
Employees 1,279
Stock Exchange NasdaqGM
Ticker Symbol ALVOW
Website https://www.alvotech.com
Financial Performance
In 2025, Alvotech's revenue was 586.32M, an increase of 19.74% compared to the previous year's 489.68M. Earnings were 27.92M, a decrease of -112.04%.
Financial Statements
Page 1 of 2